Cargando…

MicroRNA-101 expression is associated with JAK2V617F activity and regulates JAK2/STAT5 signaling

Detalles Bibliográficos
Autores principales:	Pagano, Francesca, Comoglio, Federico, Grinfeld, Jacob, Li, Juan, Godfrey, Anna, Baxter, Joanna, Silber, Yvonne, Green, Anthony R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5989937/ https://www.ncbi.nlm.nih.gov/pubmed/29483713 http://dx.doi.org/10.1038/s41375-018-0053-9

Ejemplares similares

The JAK-STAT pathway and hematopoietic stem cells from the JAK2 V617F perspective
por: Staerk, Judith, et al.
Publicado: (2012)

JAK2V617F-Positive Endothelial Cells Induce Apoptosis and Release JAK2V617F-Positive Microparticles
por: Hekimoğlu, Hilal, et al.
Publicado: (2022)

The JAK2 V617F mutation in isolated neutropenia
por: Langabeer, Stephen E.
Publicado: (2018)

Iron deficiency in JAK2 exon12 and JAK2-V617F mutated polycythemia vera
por: Liu, Dan, et al.
Publicado: (2021)

Prognostic significance of ASXL1, JAK2V617F mutations and JAK2V617F allele burden in Philadelphia-negative myeloproliferative neoplasms
por: Yonal-Hindilerden, Ipek, et al.
Publicado: (2015)

Anti-Glucosylsphingosine Autoimmunity, JAK2V617F-Dependent Interleukin-1β and JAK2V617F-Independent Cytokines in Myeloproliferative Neoplasms
por: Allain-Maillet, Sophie, et al.
Publicado: (2020)

Clinical features and outcomes of JAK2 V617F-positive polycythemia vera and essential thrombocythemia according to the JAK2 V617F allele burden
por: Lee, A-Jin, et al.
Publicado: (2021)

JAK2 V617F and the evolving paradigm of polycythemia vera
por: Means, Robert T.
Publicado: (2010)

Hemochromatosis, Erythrocytosis and the JAK2 p.V617F Mutation
por: Langabeer, Stephen E.
Publicado: (2017)

JAK2 mutants (e.g., JAK2V617F) and their importance as drug targets in myeloproliferative neoplasms
por: Gäbler, Karoline, et al.
Publicado: (2013)

Absence of JAK2V617F Mutated Endothelial Colony-Forming Cells in Patients With JAK2V617F Myeloproliferative Neoplasms and Splanchnic Vein Thrombosis
por: Guy, Alexandre, et al.
Publicado: (2020)

The telomerase inhibitor imetelstat differentially targets JAK2V617F versus CALR mutant myeloproliferative neoplasm cells and inhibits JAK-STAT signaling
por: Olschok, Kathrin, et al.
Publicado: (2023)

JAK2V617F Allele Burden Measurement in Peripheral Blood of Iranian Patients with Myeloproliferative Neoplasms and Effect of Hydroxyurea on JAK2V617F Allele Burden
por: Ferdowsi, Shirin, et al.
Publicado: (2016)

JAK out of the box: myeloproliferative neoplasms--associated JAK2 V617F mutations contribute to aortic aneurysms
por: Elf, Shannon E.
Publicado: (2021)

Self-Renewal of Single Mouse Hematopoietic Stem Cells Is Reduced by JAK2V617F Without Compromising Progenitor Cell Expansion
por: Kent, David G., et al.
Publicado: (2013)

Paroxysmal nocturnal hemoglobinuria and concurrent JAK2(V617F) mutation
por: Sugimori, C, et al.
Publicado: (2012)

International external quality assurance of JAK2 V617F quantification
por: Asp, Julia, et al.
Publicado: (2018)

The JAK2 V617F mutation in retinal vein or artery occlusion
por: Langabeer, Stephen E.
Publicado: (2019)

Chorea Associated with JAK2(V617F) ‐Positive Essential Thrombocythemia
por: Calculli, Alessandra, et al.
Publicado: (2022)

Impact of JAK2V617F Mutation Burden on Disease Phenotype in Chinese Patients with JAK2V617F-positive Polycythemia Vera (PV) and Essential thrombocythemia (ET)
por: Zhao, Shixiang, et al.
Publicado: (2016)

Identification of AIM2 as a downstream target of JAK2V617F
por: Liew, Ei Leen, et al.
Publicado: (2016)

PB2178: EVALUATION OF JAK2 EXON 12 MUTATIONS IN PATIENTS WITH JAK2 (V617F)-NEGATIVE POLYCYTHEMIA VERA
por: Khosravi, Sahar, et al.
Publicado: (2023)

JAK2 and Beyond: JAK2V617 Mutational Study of Myeloproliferative Disorders and Haematological Malignancies
por: Syeed, Nidda
Publicado: (2019)

JAK2-V617F-induced MAPK activity is regulated by PI3K and acts synergistically with PI3K on the proliferation of JAK2-V617F-positive cells
por: Wolf, Alexandra, et al.
Publicado: (2013)

PB2192: JAK2 V617F ALLELE BURDEN AND THROMBOTIC EVENTS IN PATIENTS WITH JAK2 V617F POSITIVE POLYCYTHEMIA VERA OR ESSENTIAL THROMBOCYTHEMIA AT HIGH RISK OF THROMBOSIS
por: Hwang, Yun Hui, et al.
Publicado: (2023)

P1008: THE TELOMERASE INHIBITOR IMETELSTAT DIFFERENTIALLY TARGETS JAK2V617F- VERSUS CALR-MUTANT MYELOPROLIFERATIVE NEOPLASM CELLS AND INHIBITS JAK-STAT SIGNALING
por: Olschok, Kathrin, et al.
Publicado: (2023)

Differential roles of STAT1 and STAT2 in the sensitivity of JAK2V617F- vs. BCR-ABL-positive cells to interferon alpha
por: Schubert, Claudia, et al.
Publicado: (2019)

JAK2-tree: a simple CBC-based decision rule to guide appropriate JAK2 V617F mutation testing
por: Mahe, Etienne, et al.
Publicado: (2019)

JAK2 V617F: A Single Mutation in the Myeloproliferative Group of Disorders
por: McLornan, Donal, et al.
Publicado: (2006)

Molecular Pathogenesis and Therapy of Polycythemia Induced in Mice by JAK2 V617F
por: Zaleskas, Virginia M., et al.
Publicado: (2006)

Gender and Vascular Complications in the JAK2 V617F-Positive Myeloproliferative Neoplasms
por: Stein, Brady L., et al.
Publicado: (2011)

Development of a highly sensitive method for detection of JAK2V617F
por: Zhao, Anna H, et al.
Publicado: (2011)

Crystal structures of the Jak2 pseudokinase domain and the pathogenic mutant V617F
por: Bandaranayake, Rajintha M., et al.
Publicado: (2012)

Jak2V617F myeloproliferative neoplasm stem cells and interferon-alpha
por: Lane, Steven W., et al.
Publicado: (2013)

Detection of JAK2 V617F mutation increases the diagnosis of myeloproliferative neoplasms
por: ZHANG, SHU-PENG, et al.
Publicado: (2015)

Acute promyelocytic leukemia with JAK2 V617F and severe differentiation syndrome
por: Braun, Theodore P., et al.
Publicado: (2014)

Essential thrombocytemia following immune thrombocytopenia with JAK2V617F mutation
por: Caocci, Giovanni, et al.
Publicado: (2017)

Exploring redox vulnerabilities in JAK2(V617F)-positive cellular models
por: Lima, Keli, et al.
Publicado: (2021)

Clonal Hematopoiesis and JAK2V617F Mutations in Patients With Cardiovascular Disease
por: Yokokawa, Tetsuro, et al.
Publicado: (2021)

Crucial role of hematopoietic JAK2 V617F in the development of aortic aneurysms
por: Yokokawa, Tetsuro, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_0865lue9j0v17ukl3h5ianojnf